March 12, 2012
The National Institute for Health and Clinical Excellence (NICE) on Friday recommended Merck & Co.'s new hepatitis C drug Victrelis (boceprevir) for use in Britain's state health service. Although it often shuns expensive new treatments on cost grounds, NICE noted that the significant improvements seen with Victrelis make it a cost-effective option. Victrelis costs £30,800 (US $48,109) for a 44-week regimen; it is designed to be administered with peginterferon-alfa and ribavirin, which add £11,000 (US $17,178) to the total. The draft guidelines are open for consultation before final approval.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|Free Your (and Carl's) Mind: An Open Letter to Anthony Fauci About HIV Prevention Research Priorities|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|
|Thank You, Paul Kawata: Reflections on USCA and Being a Gay Man of a Certain Age|